Andrew Dunn

@AndrewE_Dunn

Pharma and biotech reporter for Say hello: adunn@businessinsider.com

Washington, DC
Vrijeme pridruživanja: ožujak 2015.
Rođen/a 11. srpnja

Tweetovi

Blokirali ste korisnika/cu @AndrewE_Dunn

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @AndrewE_Dunn

  1. Prikvačeni tweet
    21. sij

    The fabled PERSONAL NEWS tweet: Today’s my first day as Business Insider’s pharma and biotech reporter! So excited to keep covering the industry as part of BI’s healthcare team — get in touch, everyone.

    Poništi
  2. prije 14 sati

    Worth a read if you missed it earlier today: has a great explanation of Regeneron's coronavirus R&D plan

    Poništi
  3. prije 18 sati

    Vaccine efforts against will likely take years, with history as a guide. The hope with testing some antivirals already on market is that timeline could be much quicker in getting patients a treatment:

    Poništi
  4. proslijedio/la je Tweet

    Fun one up this morning: I spoke to CEO about the three "R's" he's used to guide his career.

    Poništi
  5. proslijedio/la je Tweet

    +13% on winning patent challenge to Tecfidera vs

    Poništi
  6. prije 19 sati

    A milestone in cancer and cloud genomics. “The broad availability and quality of the new data set will almost certainly spur a wave of biological insights.” write U-Mich. researchers Marcin Cieslik and Arul Chinnaiyan in a commentary piece here:

    Prikaži ovu nit
    Poništi
  7. prije 19 sati

    Nature's main link isn't live yet, but here's an editorial describing the effort that is up:

    Prikaži ovu nit
    Poništi
  8. prije 19 sati

    Nature just published 20+ papers based off one of the largest collaborative efforts in cancer research: 1,300+ scientists sequencing 2,658 whole genomes from 37 countries in 38 different tumor types. Full collection of Nature papers, out now:

    Prikaži ovu nit
    Poništi
  9. prije 21 sat

    ICYMI: I wrote about the leading drug industry responses to the coronavirus epidemic. Includes and here:

    Poništi
  10. 5. velj

    Going into , here’s what Capital Alpha healthcare analysts wrote on if Trump makes no reference to the IPI model (he didn’t): “If Trump doesn’t make any decisive comments on the model, we’d question whether he has a viable plan for acting on it.”

    Poništi
  11. proslijedio/la je Tweet

    on call: No knowledge of additional responses to remdesivir. Waiting for clinical data. On manufacturing capacity: “We are investing heavily to be prepared as best we can.”

    Poništi
  12. 4. velj

    To say the least, this has been a fast-moving space. J&J, Regeneron, Gilead and others have all disclosed R&D plans for curing or treating the novel coronavirus. Here's the latest round-up on all their efforts:

    Poništi
  13. proslijedio/la je Tweet
    4. velj

    real nice overview from on how big pharma is gearing up to fight the Wuhan coronavirus:

    Poništi
  14. 4. velj

    George Yancopoulos on coronavirus R&D efforts: "The life-saving results seen with our investigational Ebola therapy last year underscore the potential impact of Regeneron's rapid response platform for addressing emerging outbreaks." PR here:

    Poništi
  15. 4. velj

    a16z's growth in biotech/healthcare investing: 2015: $200m fund + hire Vijay Ponde 2017: $450m fund + add 2019: Add Julie Yoo as GP 2020: $750m fund + add Here's what the Bio Fund 3 team is targeting:

    Poništi
  16. proslijedio/la je Tweet
    3. velj

    Coronavirus testing needs to be more widespread, former FDA Commissioner Dr. Scott Gottlieb says. “We have to assume it’s already here and circulating.”

    Poništi
  17. 31. sij

    Simple — yet stunning — graphic to see. # of confirmed cases of coronavirus in China, per daily situation reports from WHO. Just under 25,000 cases if you add suspected cases in China.

    Poništi
  18. proslijedio/la je Tweet

    This week's Dispensed is out! In it: - So much on + the primary care biz overall - 's insights from biotech/pharma earnings - my deep-dive on 's partnership strategy Subscribe!

    Poništi
  19. 31. sij

    Just published in The Lancet: a new model by U. of Hong Kong researchers says 75,800 individuals in Wuhan may have been infected w/ coronavirus as of Jan. 25. Also says multiple major Chinese cities may have enough cases for local epidemics.

    Poništi
  20. 31. sij

    Amgen's recent R&D on kidney disease hasn't brought "game-changing innovation," CEO Bob Bradway said yesterday, so is turning to M&A/BD to bring in external assets. up 8% today, a top Wall Street takeout target working in the kidney space.

    Poništi
  21. proslijedio/la je Tweet

    Here we go: One Medical is set to start trading today after raising $245 million in its IPO

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·